Educational only, not medical advice: Eloralintide is an investigational drug from Eli Lilly. It is not FDA-approved, and "Elora" vials sold online are research chemicals made outside Lilly's trials. Nothing here is a personal plan or dosing advice. Talk to a qualified healthcare provider before trying anything still in clinical trials.
Asked in the community
"Does anyone have links or helpful info about Elora? I'm thinking about trying it but wanted to do a bit of research first."
Short Answer
"Elora" is eloralintide, an experimental once-weekly injection from Eli Lilly that mimics amylin, a hormone involved in feeling full. In a 48-week Phase 2 trial of 263 adults published in The Lancet, average weight loss ranged from 9.5% to 20.1% depending on dose, versus 0.4% on placebo. Nausea and fatigue were the most common side effects. It is still in Phase 3 trials and is not FDA-approved.
What Is Elora (Eloralintide)?
Eloralintide, code name LY3841136, is a long-acting, selective amylin receptor agonist. Amylin is a hormone released alongside insulin after meals, and it helps signal fullness. Lilly says eloralintide's effect likely comes from reduced calorie intake through greater satiety. That makes it a different mechanism from semaglutide, tirzepatide and retatrutide, which all act on the GLP-1 pathway. "Elora" is simply the short name research-chemical vendors use for it.
What the Research Shows
The main human evidence is one Phase 2 trial, published in The Lancet in 2025. It enrolled 263 adults with obesity, or overweight plus at least one weight-related condition, and without type 2 diabetes, across 46 US sites. People took weekly injections at several doses for 48 weeks.
- Weight loss: average weight loss ranged from 9.5% at the lowest dose (1 mg) to 20.1% at the highest (9 mg), compared with 0.4% on placebo, using Lilly's efficacy estimand.
- Other measures: Lilly reported improvements in waist size, blood pressure, lipids, blood sugar and inflammation markers.
- What's missing: this is one mid-stage trial. Long-term safety, results in people with diabetes, and head-to-head comparisons with GLP-1 drugs are still being studied.
Side Effects Reported
The most common side effects in the Phase 2 trial were nausea and fatigue, mostly mild to moderate and more frequent at higher doses. Published summaries put nausea at up to 64% (6 mg) and fatigue at up to 46% (6 to 9 mg). Slower dose escalation was one of the schemes the trial tested.
Where It Stands Now
Lilly began Phase 3 trials in early 2026. They include a trial in adults without diabetes, one in adults with type 2 diabetes, and one in people who stay overweight while already taking a weekly GLP-1 drug. Lilly is also testing eloralintide combined with tirzepatide. Until those trials finish and the FDA reviews the data, eloralintide is investigational and not approved.
Before You Try It
Research-chemical "Elora" is not the drug Lilly tested. It is made outside the trials, with no FDA oversight of what is in the vial. If you are researching it, a few things are worth doing:
- Get the COA for your exact batch and check that the lot number matches your vial. See How to Read a Peptide COA.
- Look for identity and endotoxin testing, not just a purity percentage.
- Talk to a doctor, especially if you have diabetes, take other weight-loss or blood-sugar medicines, or are pregnant or trying to conceive.
Have a COA for an Elora vial?
Upload it to the free COA checker. It flags missing lot numbers, identity and endotoxin testing, and links to the lab's own lookup.
Related Reading
Compare the GLP-1 drugs in Retatrutide vs Tirzepatide, see Peptides for Fat Loss for the wider landscape, or browse more peptide questions answered.
Have a question of your own?
Ask it in the BioStackIQ community. Good questions get a full, sourced answer like this one.
Frequently Asked Questions
What is Elora?
"Elora" is the short name research-chemical vendors use for eloralintide (LY3841136), an investigational once-weekly injection from Eli Lilly. It is a selective amylin receptor agonist, meaning it mimics amylin, a hormone that helps signal fullness after meals.
How much weight did people lose on eloralintide?
In a 48-week Phase 2 trial of 263 adults published in The Lancet in 2025, average weight loss ranged from 9.5% at the 1 mg dose to 20.1% at the 9 mg dose, compared with 0.4% on placebo.
What are the side effects of eloralintide?
In the Phase 2 trial, the most common side effects were nausea and fatigue, mostly mild to moderate and more frequent at higher doses. Published summaries report nausea in up to 64% and fatigue in up to 46% of participants in the higher-dose groups.
Is eloralintide FDA-approved?
No. Eloralintide is investigational. Eli Lilly began Phase 3 trials in early 2026, and it is not approved by the FDA. Vials sold online as "Elora" are research chemicals made outside Lilly's trials.
How is eloralintide different from semaglutide or tirzepatide?
Semaglutide and tirzepatide act on the GLP-1 pathway (tirzepatide also on GIP). Eloralintide acts on amylin receptors instead, a separate fullness signal. Lilly is also testing eloralintide combined with tirzepatide.